Clinical Studies Overview | Orbactiv® (oritavancin) for injection
Frontiers | PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts? | Oncology
Lynparza extended survival of ovarian cancer patients' < Pharma < 기사본문 - KBR
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
PARPi in OC - Ovarian Cancer PARPi Therapy - Module - PARP Inhibitors in Ovarian Cancer - Oncology - Clinical Care Options
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Efficacy of LYNPARZA® (olaparib) for Maintenance of BRCAm Advanced Ovarian Cancer
SOLO 1 and SOLO 2 Trials Could Strengthen Dupixent's Label
sólo1 - Twitter Search / Twitter
Olaparib Maintenance Reduces the Risk of Recurrence in Newly
The forefront of ovarian cancer therapy: update on PARP inhibitors - Annals of Oncology
PARPi in OC - Ovarian Cancer PARPi Therapy - Module - PARP Inhibitors in Ovarian Cancer - Oncology - Clinical Care Options
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
Current status and future prospects of PARP inhibitor clinical trials | CMAR
Efficacy of LYNPARZA® (olaparib) for Maintenance of BRCAm Advanced Ovarian Cancer
SOLO-1 Phase III trial demonstrates Lynparza maintenance therapy cut risk of disease progression or death by 70% in patients with newly-diagnosed, advanced BRCA-mutated ovarian cancer
Journal of Clinical Oncology al Twitter: "Subgroup efficacy analysis of olaparib maintenance in patients with newly diagnosed ovarian cancer and a BRCA mutation in the SOLO1 trial https://t.co/LE5aobw4It #gyncsm #JCO https://t.co/PtyzfMMMIN" /
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer - ScienceDirect
SOLO-1 Trial
PARPi in OC - Ovarian Cancer PARPi Therapy - Module - PARP Inhibitors in Ovarian Cancer - Oncology - Clinical Care Options
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3
PARP inhibitors as first-line maintenance treatment for ovarian cancer: Translating the latest data to clinical practice - touchONCOLOGY
Efficacy of LYNPARZA® (olaparib) for Maintenance of BRCAm Advanced Ovarian Cancer
Advances in ovarian cancer, from biology to treatment | Nature Cancer
